Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody

Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody Molecular Therapy 24, 1634 (september 2016). doi:10.1038/mt.2016.141 Authors: Ursula Jördis Eva Seidel, Patrick Schlegel, Ludger Grosse-Hovest, Martin Hofmann, Steffen Aulwurm, Elwira Pyz, Friedhelm R Schuster, Roland Meisel, Martin Ebinger, Tobias Feuchtinger, Heiko-Manuel Teltschik, Kai-Erik Witte, Carl-Philipp Schwarze, Hans-Georg Rammensee, Rupert Handgretinger, Gundram Jung & Peter Lang
Source: Molecular Therapy - Category: Genetics & Stem Cells Authors: Source Type: research